

Advancements in Neuroimaging for Early Detection of Neurological Disorders

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

The rising costs and frequency of neurological illnesses, particularly Alzheimer's disease and vascular dementia, emphasise the need for early detection and intervention. Recent advances in neuroimaging technologies have greatly improved our ability to detect and monitor these disorders at an early stage. This paper examines the most recent breakthroughs in neuroimaging, with a focus on resting-state functional MRI, presymptomatic detection in Alzheimer's research, diffusion tensor imaging for white matter analysis, and magnetoencephalography. The debate also focuses on the integration of various techniques for more precise detection and their potential advantages to healthcare. Through evaluating the historical context, present approaches, and future perspectives, this study seeks to highlight neuroimaging's transformative potential in improving patient outcomes and lowering healthcare expenditures.

Keywords: Neuroimaging, Early Detection, Alzheimer's Disease, Functional MRI, Diffusion Tensor Imaging

INTRODUCTION

Advancements in neuroimaging for early detection of neurological disorders. Direct healthcare costs in the United States increased for Alzheimer's disease and vascular dementia in the last three years. This outcome is largely due to the increasing prevalence of conditions such as Alzheimer's disease. Timely diagnosis has been associated with improved outcomes in individuals diagnosed with neurological disorders. Researchers are heavily focused on the system-level organization of the human brain as it relates to cognitive function and behavior as technological advancements occur. Neuroimaging technology utilizes multiple imaging techniques to explore structure and function from both the molecular and chemical levels to whole brain function. Common modalities include computed tomography, positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging, and functional resonance imaging. When researchers examine how the brain operates in health and disease, neuroimaging is used for in vivo investigation [1, 2]. The main purpose of this manuscript is to discuss some of the recent technological advancements in neuroimaging. Specifically, the essay will examine the theoretical embrace of resting state functional MRI, presymptomatic detection in Alzheimer's disease research, the use of diffusion tensor imaging to detect white matter impairments, and the innovation known as magnetoencephalography. The overlay of the latter two and how it could be used to detect specific impairments in certain diseases is also discussed. Advantages and limitations of these technologies are explored in light of the history of neuroimaging, the field's primary methodological approach, and the potential benefits of early detection intervention. Given that these diseases are progressive, the potential savings in the area of healthcare is significant as we continue to find ways to intervene with the diseases [3].

HISTORY OF NEUROIMAGING IN NEUROLOGICAL DISORDERS

Neurological disorders affect a major portion of the global population. Establishing an early diagnosis in such disorders facilitates a better treatment plan and curtails morbidity and mortality. Neuroimaging, since the development of conventional X-ray, the first method for detecting space-occupying lesions, has gone through a sea of change. Though plain film X-ray is still relevant for qualitative information from

the very beginning, it couldn't detect the underlying pathology. Advanced imaging techniques such as contrast-enhanced MRI and CT have further improved the detection and characterization of the underlying space-occupying lesions. With the normal advancement of structural vulnerable non-invasive imaging, visualization of functional changes opens up numerous research arenas, allowing the application of positron emission tomography, magnetoencephalography, single-photon emission CT, functional MRI, magnetic resonance spectroscopy, and molecular imaging [4, 5]. Research on neuroimaging in neurological disorders got a major boost after showing the atrophy of the cerebral cortex in Alzheimer's disease. However, with the advent of advanced imaging techniques, both structural and functional, the role of neuroimaging in diagnosis also increased subsequently, with brain biopsy considered the gold standard yielding in-vivo diagnosis. Further, after 30 years, a robust diagnostic tool was developed for neurodegenerative profiles, and guidelines for dementia diagnosis proposed significant shifts in brain behavior in neurology. Advances in our understanding of neurological and psychiatric disorders, especially schizophrenia and major depressive disorder, have been provided by older neuroimaging technologies. Given expertise, research applications are endlessly growing. Being initially a research platform, movement into the realm of clinical diagnosis and patient management is now being made by both functional and molecular neuroimaging. The present and near future electric neuroimaging scenario will be reviewed briefly [6].

CURRENT NEUROIMAGING TECHNIQUES

Over the past four decades, advances in different neuroimaging technologies have consistently enhanced our understanding of the structural, functional, and molecular aspects of the human brain. Multimodal neuroimaging approaches are invaluable in understanding dynamic relationships between brain function and metabolism. The recent breakthroughs in high-field MRI, such as 7T MRI, magnify these effects, further enabling measurements of metabolic, hemodynamic, and neurostructural elements of the human brain noninvasively. Other advanced MR techniques – specifically, high angular and spatial-resolution diffusion MRI and high-dimensional functional MRI – have been increasingly used to provide new methods to map neural circuits with generative models or recurrent networks in cognitive and affective domains. However, spatial and temporal limitations of these imaging techniques have prevented the detection of various complex and chronic brain abnormalities in fundamental neurological-affective disorders. These limitations motivated the development of the BRAIN Initiative and its extension, known as the BRAIN Initiative 2.0 since 2018. The goal is to revolutionize our understanding of the human brain in health and disease [7, 8].

APPLICATIONS OF NEUROIMAGING IN EARLY DETECTION

Neuroimaging is becoming increasingly useful in the early diagnosis and monitoring of neurological disorders. Identifying structural and functional biomarkers is important to delineate the underlying cellular mechanisms involved in the cognitive, motor, and behavioral impairments commonly found in this population. Neuroimaging techniques are widely used to identify these diagnostic biomarkers in an in vivo manner. Few specific clinical applications are performed to monitor disease evolution by assessing new/enlarged and active lesions after starting a new treatment in a progressive patient [9, 10]. Another relevant application for patients, families, and society is the diagnosis of pre-symptomatic individuals. Very pre-symptomatic markers of neurodegenerative diseases can potentially be detected even more than 20 years before symptom initiation. There is also an increasing number of examples in different diseases in which a complete structural, functional, neuropathological, and clinical patient characterization is mandatory not only for diagnosis but also in the field of personalized medicine application from the diagnostic and treatment intervention. The optimally applied imaging approach in many diseases is a collaboration between neurology and radiology, which can provide the best added value via integrated and multimodal/cross-sectional approaches [11, 12].

CHALLENGES AND FUTURE DIRECTIONS

Despite recent advances, there are still challenges in using neuroimaging for early detection. The accessibility of neuroimaging services and the costs associated with having regular scans are barriers. Variability in the interpretation of MRI and PET-FDG images among clinicians has been reported. Ethical considerations regarding informed consent, data ownership, and patient privacy need to be addressed. The development of AI interpretable neuroimaging is not trivial, and clinicians need to work in collaboration with data scientists and AI experts to leverage their collective expertise. As AI and neuroimaging gradually become more refined and the technology becomes more accessible, this will in turn impact the more traditional business model, which neurologists could navigate. In terms of future work, greater research is needed on creating virtual reality-based scenarios for studying the interaction between the environment, motor alterations, and the visual networks in a realistic life scenario. More research is also needed to understand the different context-dependent activation patterns due to the

inhibition of multiple neurotransmitter receptors in the basal ganglia. In contrast to the current studies, these new neuroimaging techniques may be a promising method to study the progression of Parkinson's disease, Huntington's disease, and related conditions, particularly in the prodromal stages of these diseases. In addition to the above-discussed research and methodological advancements, we now have greater knowledge of the genetic variations involved in these conditions and the presence of specific neuroinflammatory biomarkers. Integrating such new methods into studies that stress dopamine D2, D1, serotonin, opiate, endocannabinoid, adenosine, and NMDA function, together with these new molecular imaging approaches, may generate complementary results. These findings may provide advances from improved earlier diagnosis to definable pharmacological, non-pharmacological, and new molecular testable targets. This will help to guide the discovery of both predictive and prognostic tests to be used in future clinical trials. International collaborative efforts are needed to bring together interdisciplinary clinicians and scientists with internationally agreed protocols for translating basic science to clinical meaning while hopefully addressing the above confounders and reducing variability. Current work is underway in some disorders, such as Huntington's disease and multiple sclerosis, where there is collaboration across Europe and the United States, and the above methods are going to be applied to gene-positive subjects and patients to answer the above questions. The analysis of iron is also being performed in various studies, and the conduct of similar innovative work in multiple sclerosis and Huntington's disease should be encouraged. Ongoing methodological improvements are likely to provide further valid biomarkers across different levels of disease and different disorders [13, 14].

CONCLUSION

Advancements in neuroimaging have revolutionized our approach to diagnosing and managing neurological disorders. Technologies such as resting-state functional MRI, diffusion tensor imaging, and magnetoencephalography have provided unprecedented insights into the brain's structure and function, allowing for earlier and more accurate detection of diseases like Alzheimer's and other neurodegenerative conditions. Despite these advancements, challenges such as accessibility, variability in interpretation, and ethical considerations remain. Future research should focus on integrating emerging technologies and developing collaborative international efforts to enhance diagnostic precision and intervention strategies. The continued evolution of neuroimaging holds the promise of significantly improving early detection, patient outcomes, and overall healthcare efficiency.

REFERENCES

1. Lima AA, Mridha MF, Das SC, Kabir MM, Islam MR, Watanobe Y. A comprehensive survey on the detection, classification, and challenges of neurological disorders. *Biology*. 2022 Mar 18;11(3):469. [mdpi.com](https://doi.org/10.3390/biology11030469)
2. Hurford R, Sekhar A, Hughes TA, Muir KW. Diagnosis and management of acute ischaemic stroke. *Practical Neurology*. 2020 Aug 1;20(4):304-16.
3. Kalani M, Anjankar A. Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment. *Cureus*. 2024 Jun;16(6).
4. Lin L, Wang LV. The emerging role of photoacoustic imaging in clinical oncology. *Nature Reviews Clinical Oncology*. 2022 Jun;19(6):365-84.
5. Panayides AS, Amini A, Filipovic ND, Sharma A, Tsaftaris SA, Young A, Foran D, Do N, Golemati S, Kurc T, Huang K. AI in medical imaging informatics: current challenges and future directions. *IEEE journal of biomedical and health informatics*. 2020 May 29;24(7):1837-57. [ieee.org](https://doi.org/10.1109/JBHI.2020.3000000)
6. van Oostveen WM, de Lange EC. Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring. *International journal of molecular sciences*. 2021 Feb 20;22(4):2110. [mdpi.com](https://doi.org/10.3390/ijms22042110)
7. Noggle CA, Davis AS. Advances in neuroimaging. Understanding the Biological Basis of Behavior: Developing Evidence-Based Interventions for Clinical, Counseling and School Psychologists. 2021:107-37.
8. Yen C, Lin CL, Chiang MC. Exploring the frontiers of neuroimaging: a review of recent advances in understanding brain functioning and disorders. *Life*. 2023 Jun 29;13(7):1472.
9. Sobański M, Zacharzewska-Gondek A, Waliszewska-Prośół M, Szaśiadek MJ, Zimny A, Bladowska J. A review of neuroimaging in rare neurodegenerative diseases. *Dementia and geriatric cognitive disorders*. 2020 Dec 28;49(6):544-56. [karger.com](https://doi.org/10.1159/000514411)
10. Yuan J, Ran X, Liu K, Yao C, Yao Y, Wu H, Liu Q. Machine learning applications on neuroimaging for diagnosis and prognosis of epilepsy: A review. *Journal of neuroscience methods*. 2022 Feb 15;368:109441. [\[PDF\]](#)

11. Benatar M, Wu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. *Brain*. 2022 Jan 1;145(1):27-44. oup.com
12. Rauf A, Badoni H, Abu-Izneid T, Olatunde A, Rahman MM, Painuli S, Semwal P, Wilairatana P, Mubarak MS. Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases. *Molecules*. 2022 May 17;27(10):3194. mdpi.com
13. McAllister B, Gusella JF, Landwehrmeyer GB, Lee JM, MacDonald ME, Orth M, Rosser AE, Williams NM, Holmans P, Jones L, Massey TH. Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. *Neurology*. 2021 May 11;96(19):e2395-406. neurology.org
14. Mühlbäck A, van Walsem M, Nance M, Arnesen A, Page K, Fisher A, van Kampen M, Nuzzi A, Limpert R, Fossmo HL, Cruickshank T. What we don't need to prove but need to do in multidisciplinary treatment and care in Huntington's disease: a position paper. *Orphanet Journal of Rare Diseases*. 2023 Jan 30;18(1):19. springer.com

CITE AS: Kato Jumba K. (2024). Advancements in Neuroimaging for Early Detection of Neurological Disorders. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 5(2):5-8